IP Library Granted Patent US 10,076,587
Granted Patent B2
US 10,076,587 · App. 14/819,988 · Granted Sep 18, 2018

Protease modulating wound interface layer for use with negative pressure wound therapy

Inventors: Christopher Brian Locke (Bournemouth, GB); Timothy Mark Robinson (Basingstoke, GB); Breda Mary Cullen (Skipton, GB)
Assignee: KCI Licensing, Inc.
A61L15/42A61H9/0057A61L15/225A61L15/28A61L15/325A61L15/425A61L2430/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,076,587
App. No.
14/819,988
Granted
Sep 18, 2018
Kind
B2
Abstract

Systems, methods, and apparatuses for modulating proteases including matrix metalloproteinase (MMP), elastase, and bacterial protease in a negative pressure therapy system are described. A mesh having a sacrificial substrate is included. The sacrificial substrate includes a plurality of collagen fibers reinforced with a supporting material and intersecting with each other to form a network of collagen fibers having a plurality openings. The openings of the plurality of openings have an average area between about 0.5 mm 2 and about 20 mm 2 to permit the flow of negative pressure through the mesh. The sacrificial substrate can also include oxidized regenerated cellulose.

Claims (33)

1. A negative-pressure therapy system for modulating proteases in a tissue site, the system comprising:

a modulating layer including a plurality of collagen fibers reinforced with a supporting material and intersecting with each other to form a network of collagen fibers having a plurality openings;

wherein the openings of the plurality of openings have an average effective diameter between about 0.5 mm and about 5 mm to permit the flow of negative pressure through the network;

a manifold configured to be positioned adjacent the network;

a cover configured to be positioned over the manifold and the network and coupled to tissue adjacent the tissue site to form a sealed space; and

a negative-pressure source configured to be fluidly coupled to the manifold to provide negative pressure to the sealed space through the manifold and the network.

2. The method of claim 1 , wherein the openings have an average area between about 0.2 mm 2 and about 20.0 mm 2 .

3. The system of claim 1 , wherein the openings are generally circular in shape and have an average diameter between about 1 mm and about 2.5 mm.

4. The system of claim 1 , wherein the collagen fibers have a diameter of less than about 1 millimeter.

5. The system of claim 1 , wherein the collagen fibers have a diameter of between about 1 micron and 50 microns.

6. The system of claim 1 , wherein the network has a thickness between about 5 microns and about 2 millimeters.

7. The system of claim 1 , wherein the network has a thickness of about 25 microns.

8. The system of claim 1 , wherein the collagen fibers have a collagen content between about 10% and about 50% of the total material of the collagen fiber.

9. The system of claim 1 , wherein the collagen fibers comprise a string of collagen elements.

10. The system of claim 1 , wherein the supporting material comprises supporting fibers.

11. The system of claim 10 , wherein the supporting fibers are twisted with the plurality of collagen fibers.

12. The system of claim 10 , wherein the supporting fibers support separate collagen elements to form the plurality of collagen fibers.

13. The system of claim 12 , further comprising a plurality of supporting fibers operatively coupled to the plurality of collagen fibers.

14. The system of claim 12 , wherein the plurality of supporting fibers and the plurality of collagen fibers are woven together.

15. The system of claim 12 , wherein the supporting fibers are water soluble.

16. The system of claim 12 , wherein the supporting fibers are biodegradable.

17. The system of claim 12 , wherein the plurality of collagen fibers and the plurality of supporting fibers have a collagen content between about 10% and about 50% of the modulating layer.

18. The system of claim 12 , wherein the collagen fibers and supporting fibers are non-woven.

19. The system of claim 1 , wherein the collagen fibers comprise:

staple fibers formed from collagen; and

staple fibers formed from the supporting material;

wherein the staple fibers formed of collagen and the staple fibers formed of the supporting material are twisted together to form the collagen fibers.

20. The system of claim 19 , wherein the supporting material comprises one or more selected from a group consisting of: polyethylene oxide, alginate, polylactic acid, polyvinyl alcohol, polycapralactones, and polyamides.

21. The system of claim 19 , wherein a length of the staple fibers formed from collagen is between about 4 mm and about 6 mm.

22. The system of claim 19 , wherein the collagen fibers have a collagen content between about 10% and about 50% of the total material of the collagen fiber.

23. The system of claim 1 , further comprising a plurality of oxidized regenerated cellulose fibers intersecting the collagen fibers to form the network having the plurality of openings.

24. The system of claim 23 , wherein about 45% of the network comprises oxidized regenerated cellulose fibers.

25. The system of claim 23 , wherein about 55% of the network comprises collagen fibers.

Assignments (5)
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 7, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KCI USA, INC.; KCI LICENSING, INC.
Reel/Frame 050966/0547 →
RELEASE OF SECURITY INTEREST REEL/FRAME 040098/0268 Recorded Feb 8, 2017
From: WILMINGTON TRUST
To: KCI USA, INC.
Reel/Frame 041666/0320 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2016
From: LOCKE, CHRISTOPHER BRIAN; ROBINSON, TIMOTHY MARK; CULLEN, BREDA MARY
To: KCI LICENSING, INC.
Reel/Frame 037727/0235 →
Continuity (2)
Provisional Application 62035880 · Aug 11, 2014
Related Publication 20160038626A1 · Feb 11, 2016
Cited By (2)
US 12,290,655 US 12,458,540